Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer

Yasuhiro Inoue, Takashi Iwata, Yoshinaga Okugawa, Aya Kawamoto, Junichiro Hiro, Yuji Toiyama, Koji Tanaka, Keiichi Uchida, Yasuhiko Mohri, Chikao Miki, Masato Kusunoki

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)

Abstract

Objectives: The inflammation-based Glasgow Prognostic Score (GPS) is associated with outcome in a variety of cancers. This study investigated whether a modified GPS (mGPS) could predict survival in patients undergoing multimodality therapy for advanced colorectal cancer (CRC). Methods: We enrolled 245 patients with advanced CRC who received chemotherapy. The mGPS was recorded prior to first-line chemotherapy and to cytoreductive therapy including secondary surgery and/or radiofrequency ablation. The prognostic significance of the mGPS was analyzed using Kaplan-Meier, univariate, and multivariate analyses. Results: In patients who received chemotherapy alone (n = 163), the mGPS prior to chemotherapy was an independent prognostic indicator of survival [odds ratio (OR) 1.858; 95% confidence interval (CI) 1.213-2.846; p = 0.0044]. In patients who also underwent cytoreductive therapy (n = 82), the mGPS decreased after chemotherapy in 22 patients (27%) and increased in 5 (6%). In these patients, the mGPS prior to cytoreductive therapy was an independent prognostic indicator of survival (OR 3.412; 95% CI 1.198-9.720; p = 0.0216), but the mGPS prior to chemotherapy was not. Conclusions: The mGPS is an independent prognostic indicator of survival in patients undergoing multimodality therapy for advanced CRC, if recorded at a relevant time point.

Original languageEnglish
Pages (from-to)100-107
Number of pages8
JournalOncology (Switzerland)
Volume84
Issue number2
DOIs
Publication statusPublished - 12-2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this